Chemotherapy with a single chemotherapeutic agent or a combined chemotherapeutic
regimen is the clinically standardized treatment for almost all human cancers. Upregulated …

Background and Objectives: It is generally accepted that inflammatory cells found in the
tumor microenvironment are involved in the neoplastic process, promoting cell proliferation …

The limitations of current chemotherapeutic drugs are still a major issue in cancer treatment.
Thus, targeted multimodal therapeutic approaches need to be strategically developed to …

The current study aimed to identify the radiosensitizing effect of celecoxib, a selective
cyclooxygenase-2 (COX-2) inhibitor, in combination with radiotherapy in non-small-cell lung …

Radiation therapy is a common and acceptable approach for lung cancer. Although the
benefit of ionizing radiation (IR) is well-established, cancer cells can still survive via pro …

Emerging evidence supports an intertwining framework for the involvement of different
inflammatory pathways in a common pathological background for a number of disorders. Of …

The resistance to radiotherapy in lung cancer can be attributed to vasculogenic mimicry
(VM) to some extent. Celecoxib (CXB), a selective inhibitor of cyclooxygenase-2 (COX-2), is …

Skin toxicity, especially hand-foot syndrome (HFS), is one of the most common sorafenib-
induced adverse events (AEs) in hepatocellular carcinoma (HCC) patients, leading to …

Lung cancer continues to be the leading cause of cancer mortality and a serious health
problem despite the numerous advances made in the last decade and the rapid advance of …

Purpose Radioresistance is highly correlated with radiotherapy failure in clinical cancer
treatment. In the current study, we sought to examine the efficacy of Celecoxib and Afatinib …